CL2020003255A1 - Proteínas de fusión que comprenden progranulina - Google Patents
Proteínas de fusión que comprenden progranulinaInfo
- Publication number
- CL2020003255A1 CL2020003255A1 CL2020003255A CL2020003255A CL2020003255A1 CL 2020003255 A1 CL2020003255 A1 CL 2020003255A1 CL 2020003255 A CL2020003255 A CL 2020003255A CL 2020003255 A CL2020003255 A CL 2020003255A CL 2020003255 A1 CL2020003255 A1 CL 2020003255A1
- Authority
- CL
- Chile
- Prior art keywords
- progranulin
- fusion proteins
- proteins
- ftd
- polypeptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862686579P | 2018-06-18 | 2018-06-18 | |
| US201862746338P | 2018-10-16 | 2018-10-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020003255A1 true CL2020003255A1 (es) | 2021-05-28 |
Family
ID=67138158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020003255A CL2020003255A1 (es) | 2018-06-18 | 2020-12-16 | Proteínas de fusión que comprenden progranulina |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20210284702A1 (https=) |
| EP (1) | EP3807322A1 (https=) |
| JP (1) | JP7517997B2 (https=) |
| KR (1) | KR20210027377A (https=) |
| CN (1) | CN112424233A (https=) |
| AU (1) | AU2019288212B2 (https=) |
| BR (1) | BR112020025306A2 (https=) |
| CA (1) | CA3101202A1 (https=) |
| CL (1) | CL2020003255A1 (https=) |
| EC (1) | ECSP20081591A (https=) |
| IL (1) | IL279510B2 (https=) |
| MX (1) | MX2020012518A (https=) |
| PE (1) | PE20210323A1 (https=) |
| PH (1) | PH12020552189A1 (https=) |
| SG (1) | SG11202011743SA (https=) |
| TW (1) | TWI874321B (https=) |
| WO (1) | WO2019246071A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3280441T1 (sl) | 2015-04-07 | 2022-01-31 | Alector Llc | Protitelesa anti-sortilin in metoda njihove uporabe |
| AU2016270587B2 (en) * | 2015-05-29 | 2020-12-24 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a disruption in a C9ORF72 locus |
| CN110506055A (zh) | 2017-02-17 | 2019-11-26 | 戴纳立制药公司 | 工程改造的转铁蛋白受体结合多肽 |
| CR20200129A (es) | 2017-10-02 | 2020-08-22 | Denali Therapeutics Inc | Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas |
| LT3618928T (lt) | 2018-07-13 | 2023-04-11 | Alector Llc | Anti-sortilino antikūnai ir jų panaudojimo būdai |
| WO2020037150A2 (en) * | 2018-08-16 | 2020-02-20 | Denali Therapeutics Inc. | Engineered bispecific proteins |
| JP7624919B2 (ja) * | 2018-10-16 | 2025-01-31 | デナリ セラピューティクス インコーポレイテッド | プログラニュリン関連障害を処置及びモニタリングするための方法 |
| BR112021015656A2 (pt) | 2019-02-20 | 2021-10-05 | Denali Therapeutics Inc. | Anticorpos anti-trem2 e métodos de uso dos mesmos |
| PH12022551598A1 (en) * | 2019-12-23 | 2023-11-20 | Denali Therapeutics Inc | Progranulin variants |
| JP2023512450A (ja) | 2020-01-13 | 2023-03-27 | デナリ セラピューティクス インコーポレイテッド | 抗ｔｒｅｍ２抗体及びその使用方法 |
| WO2021241616A1 (ja) | 2020-05-27 | 2021-12-02 | アステラス製薬株式会社 | 抗ヒトｎｒ１抗体誘導体 |
| US20210393787A1 (en) * | 2020-06-17 | 2021-12-23 | Bioasis Technologies, Inc. | Compositions and methods for treating frontotemporal dementia |
| JP7817757B2 (ja) * | 2020-09-18 | 2026-02-19 | アイユーシーエフ－エイチワイユー（インダストリー－ユニバーシティ コーオペレーション ファウンデーション ハンヤン ユニバーシティ） | ＰＴＰｓｉｇｍａ－Ｆｃ融合タンパク質およびそれを含む薬学組成物 |
| KR102666958B1 (ko) * | 2020-09-18 | 2024-05-23 | 한양대학교 산학협력단 | PTPsigma-Fc 융합단백질 및 이를 포함하는 약학 조성물 |
| WO2022082178A2 (en) | 2020-10-14 | 2022-04-21 | Denali Therapeutics Inc. | Methods for treating and monitoring frontotemporal dementia |
| EP4229192A1 (en) | 2020-10-14 | 2023-08-23 | Denali Therapeutics Inc. | Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof |
| AU2022415476A1 (en) * | 2021-12-17 | 2024-07-04 | Denali Therapeutics Inc. | Fusion proteins comprising alpha-l-iduronidase enzymes and methods |
| EP4508206A1 (en) * | 2022-04-12 | 2025-02-19 | F. Hoffmann-La Roche AG | Fusion proteins targeted to the central nervous system |
| EP4526344A1 (en) * | 2022-05-16 | 2025-03-26 | Denali Therapeutics Inc. | Transferrin receptor-binding domains and proteins comprising the same |
| JP2026501108A (ja) * | 2022-12-06 | 2026-01-14 | プロテインキュア インコーポレイテッド | ソルチリンの標的化 |
| US20250000992A1 (en) | 2023-06-21 | 2025-01-02 | Eli Lilly And Company | Compounds for the delivery of granulin across the blood brain barrier |
| WO2025051953A1 (en) * | 2023-09-07 | 2025-03-13 | Novo Nordisk A/S | Sortilin-1 binders, constructs and uses thereof |
| TW202542190A (zh) | 2023-12-20 | 2025-11-01 | 美商戴納立製藥公司 | 包含酸性α—葡萄糖苷酶之融合蛋白及其方法 |
| WO2025166077A1 (en) * | 2024-01-31 | 2025-08-07 | Alector Llc | Compositions comprising progranulin and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120039865A1 (en) * | 2008-08-19 | 2012-02-16 | Yale University | Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin |
| SI3280441T1 (sl) * | 2015-04-07 | 2022-01-31 | Alector Llc | Protitelesa anti-sortilin in metoda njihove uporabe |
| HUE057952T2 (hu) * | 2015-06-24 | 2022-06-28 | Hoffmann La Roche | Anti-transzferrin receptor antitestek testreszabott affinitással |
| WO2018024162A1 (en) * | 2016-08-03 | 2018-02-08 | Sunshine Lake Pharma Co., Ltd. | Glp-1 fusion protein comprising mutated immunoglobulin fc portion |
| US10143187B2 (en) | 2017-02-17 | 2018-12-04 | Denali Therapeutics Inc. | Transferrin receptor transgenic models |
| WO2018152285A1 (en) | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Transferrin receptor transgenic models |
-
2019
- 2019-06-18 WO PCT/US2019/037695 patent/WO2019246071A1/en not_active Ceased
- 2019-06-18 JP JP2020570444A patent/JP7517997B2/ja active Active
- 2019-06-18 CN CN201980039158.0A patent/CN112424233A/zh active Pending
- 2019-06-18 PE PE2020002083A patent/PE20210323A1/es unknown
- 2019-06-18 KR KR1020217001552A patent/KR20210027377A/ko not_active Ceased
- 2019-06-18 MX MX2020012518A patent/MX2020012518A/es unknown
- 2019-06-18 IL IL279510A patent/IL279510B2/en unknown
- 2019-06-18 BR BR112020025306-5A patent/BR112020025306A2/pt unknown
- 2019-06-18 EP EP19735097.8A patent/EP3807322A1/en active Pending
- 2019-06-18 SG SG11202011743SA patent/SG11202011743SA/en unknown
- 2019-06-18 TW TW108121124A patent/TWI874321B/zh active
- 2019-06-18 AU AU2019288212A patent/AU2019288212B2/en active Active
- 2019-06-18 CA CA3101202A patent/CA3101202A1/en active Pending
- 2019-06-18 US US17/253,391 patent/US20210284702A1/en not_active Abandoned
-
2020
- 2020-12-11 PH PH12020552189A patent/PH12020552189A1/en unknown
- 2020-12-16 EC ECSENADI202081591A patent/ECSP20081591A/es unknown
- 2020-12-16 CL CL2020003255A patent/CL2020003255A1/es unknown
-
2023
- 2023-04-12 US US18/299,458 patent/US20230406898A1/en not_active Abandoned
-
2025
- 2025-02-04 US US19/044,856 patent/US20260001925A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL279510B2 (en) | 2025-11-01 |
| US20230406898A1 (en) | 2023-12-21 |
| AU2019288212B2 (en) | 2026-04-16 |
| MX2020012518A (es) | 2021-02-16 |
| IL279510A (en) | 2021-01-31 |
| US20210284702A1 (en) | 2021-09-16 |
| ECSP20081591A (es) | 2021-01-29 |
| BR112020025306A2 (pt) | 2021-03-09 |
| PH12020552189A1 (en) | 2021-06-28 |
| PE20210323A1 (es) | 2021-02-18 |
| IL279510B1 (en) | 2025-07-01 |
| TWI874321B (zh) | 2025-03-01 |
| JP7517997B2 (ja) | 2024-07-17 |
| EP3807322A1 (en) | 2021-04-21 |
| JP2021527656A (ja) | 2021-10-14 |
| KR20210027377A (ko) | 2021-03-10 |
| AU2019288212A1 (en) | 2020-12-03 |
| WO2019246071A1 (en) | 2019-12-26 |
| TW202016152A (zh) | 2020-05-01 |
| SG11202011743SA (en) | 2021-01-28 |
| US20260001925A1 (en) | 2026-01-01 |
| CA3101202A1 (en) | 2019-12-26 |
| CN112424233A (zh) | 2021-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020003255A1 (es) | Proteínas de fusión que comprenden progranulina | |
| PE20230036A1 (es) | Variantes de progranulina | |
| CL2022000036A1 (es) | Polipéptidos modificados y usos de los mismos (divisional de solicitud no. 201900261) | |
| CY1124309T1 (el) | Τροποποιημενα πολυπεπτιδια fgf-21 και χρησεις εξ αυτων | |
| CL2019002922A1 (es) | Anticuerpos anti-péptido beta amiloide n3pglu y sus usos. | |
| MX378790B (es) | Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes. | |
| CL2022001712A1 (es) | Variantes de progranulina | |
| CO2018002450A2 (es) | Proteínas de fusión de gitrl y usos de las mismas | |
| MX2020006635A (es) | Proteína de fusión enzimática terapéutica que tiene una nueva estructura y uso de la misma. | |
| CY1122644T1 (el) | Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων | |
| CR20190480A (es) | Uso de antagonistas de klk5 para el tratamiento de una enfermedad | |
| MX2021007235A (es) | Tubulisinas y conjugados de proteina-tubulisina. | |
| JOP20220068A1 (ar) | بروتينات اندماج nkg2d واستخداماتها | |
| AR110871A1 (es) | Proteínas de fusión de factor ix y métodos de fabricación y uso de las mismas | |
| MX2022014899A (es) | Variantes y composiciones del lfa3 y sus usos. | |
| AR115565A1 (es) | Proteínas de fusión que comprenden progranulina | |
| EA202190062A1 (ru) | Слитые белки, содержащие програнулин | |
| AR119984A1 (es) | Proteínas de fusión nkg2d y sus usos | |
| TH72941B (th) | อุปกรณ์สำหรับการนำส่งสิ่งปลูกฝังเทียมและวิธีการใช้พวกมัน | |
| TH180250A (th) | อุปกรณ์สำหรับการนำส่งสิ่งปลูกฝังเทียมและวิธีการใช้พวกมัน | |
| BR112018071123A2 (pt) | (+)-azasetron para uso no tratamento de distúrbios de ouvido | |
| UA97336U (en) | Glasses-transformers |